Skip to content

Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors

A Prospective Open Pilot Study With Functional Placebo-control to Evaluate the Efficacy and Tolerability/Safety of a Subretinal Implant in Blind Patients in Accordance With ICH/GCP Guidelines

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00515814
Enrollment
15
Registered
2007-08-14
Start date
2005-09-30
Completion date
2009-12-31
Last updated
2011-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinitis Pigmentosa

Keywords

Legal blindness, Retinopathy pigmentosa, Hereditary condition, Photo-receptor degeneration, Retina implant, Subretinal implant

Brief summary

The outcome of this trial will reveal the possibilities of the retinal implant to improve the situation of patients with hereditary retinal blindness caused by degenerations of the outer retina. This pilot study will give important information on safety and efficacy of sub-retinal implants.

Detailed description

Although the design of the chip with a possible resolution of up to 1500 image points has the potential of providing object recognition, the quality of the image transmitted in this first human application cannot be foreseen. On the other hand clinical experience teaches us that even bare light recognition improves mobility of patients because of the ability to localize bright light sources such as windows or lamps.

Interventions

DEVICERetina implant is surgically placed into subretinal position

Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation & mobility.

Sponsors

Retina Implant AG
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 78 Years
Healthy volunteers
No

Inclusion criteria

* Hereditary retinal degeneration of the outer retinal layers with the retinal vessels still being perfused and pigments of mild to moderate density * Blindness (at least monocular) or visual functions not appropriate for navigation/orientation * Period of appropriate visual functions \> 12 years / lifetime * Visual acuity ≥ 0,05 in earlier life * Electrically Evoked Phosphenes provide evidence of inner-retinal function. * willing and able to give written informed consent

Exclusion criteria

* Any other ophthalmologic disease with relevant effect upon visual function (e.g. glaucoma, optic neuropathy, trauma, diabetic retinopathy, retinal detachment) * Systemic disease that might imply considerable risk with regard to the surgical intervention and anesthesia (e.g. cardiovascular diseases, severe metabolic diseases) * Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression ) * Retina detected as too thin (\< 100 µm) to expect required rest-functionality as shown via Optical Coherence Tomography (OCT). * Women who are pregnant or nursing, or women of childbearing potential who are not willing to use a medically acceptable means of birth control for the duration of the study, or women unwilling to perform a pregnancy test before entering the study * Participation in another clinical trial within the past 30 days

Design outcomes

Primary

MeasureTime frame
Visual Acuity / Light-perception / Object-orientation are significantly improved with implant-ON versus OFF as shown via FrACT / BaLM / grating test (i.e. EFFICACY)within implantation period
Patient treatment shows acceptable results (i.e. SAFETY)within implantation period

Secondary

MeasureTime frame
Activities of Daily Living are significantly improved with implant-ON versus OFF, as shown via Tasks of Daily Living test / Orientation & Mobility test (i.e. EFFICACY)within implantation period
Non-acceptable surgical complications will terminate clinical study (i.e. SAFETY)within implantation period

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026